(3R)-3-amino-2-methyl-pentan-2-ol | 74608-27-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (3R)-3-amino-2-methyl-pentan-2-ol
• 英文别名: (R)-3-Amino-2-methyl-2-pentanol；(3R)-3-amino-2-methylpentan-2-ol；(R)-3-amino-2-methyl-pentan-2-ol
• CAS: 74608-27-8
• 化学式: C₆H₁₅NO
• 分子量: 117.191
• InChiKey: RJQQAAMUEHNMSQ-RXMQYKEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-benzyl-2-fluoro-9-isopropyl-purin-6-amine 、 (3R)-3-amino-2-methyl-pentan-2-ol 在 N,N-二异丙基乙胺 作用下， 以 二甲基亚砜 、 正丁醇 为溶剂， 反应 72.0h， 以16%的产率得到6-benzylamino-2-[(1R)-1-ethyl-2-hydroxy-2-methylpropylamino]-9-isopropylpurine
  参考文献：
  名称：

  Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors

  摘要：

  The cyclin-dependent kinase (CDK) inhibitor seliciclib (1, CYC202) is in phase II clinical development for the treatment of cancer. Here we describe the synthesis of novel purines with greater solubility, lower metabolic clearance, and enhanced potency versus CDKs. These compounds exhibit novel selectivity profiles versus CDK isoforms. Compound alpha SbR-21 inhibits CDK2/cyclin E with IC(50) = 30 nM, CDK7-cyclin H with IC(50) = 1.3 mu M, and CDK9-cyclinT with IC(50) = 0.11 mu M; it (CCT68127) inhibits growth of HCT116 colon cancer cells in vitro with GI(50) = 0.7 mu M; and shows antitumour activity when dosed p.o. at 50 mg/kg to mice bearing HCT116 solid human tumour xenografts. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.08.051
• 作为产物：
  描述：

  tert-butyl N-[(1R)-1-ethyl-2-hydroxy-2-methylpropyl]carbamate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 (3R)-3-amino-2-methyl-pentan-2-ol
  参考文献：
  名称：

  [EN] MODIFIED ISOINDOLINONES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS
  [FR] ISOINDOLINONES MODIFIÉES EN TANT QU'INHIBITEURS DE GLUCOSYLCÉRAMIDE SYNTHASE

  摘要：

  本发明涉及式（I）化合物及其药学上可接受的盐或前药。本发明还涉及包含至少一种式（I）化合物的组合物，以及使用式（I）化合物治疗或预防溶酶体贮积病、神经退行性疾病、囊性疾病、癌症或与葡糖鞘氨醇脂（GlcCer）、葡糖鞘氨醇（GlcSph）和/或其他葡糖鞘氨醇基糖脂（GSL）水平升高相关的疾病或障碍的方法。

  公开号：

  WO2022115301A1

文献信息

• Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate
  作者：Yong-Kang Zhang、Jacob J. Plattner、Eric E. Easom、Robert T. Jacobs、Denghui Guo、Yvonne R. Freund、Pamela Berry、Vic Ciaravino、John C. L. Erve、Philip J. Rosenthal、Brice Campo、Francisco-Javier Gamo、Laura M. Sanz、Jianxin Cao

  DOI：10.1021/acs.jmedchem.7b00621

  日期：2017.7.13

  resistant to chloroquine and pyrimethamine. The rapid parasite in vitro reduction and in vivo parasite clearance profile of 46 were similar to those of artemisinin and chloroquine, two rapid-acting antimalarials. It was nongenotoxic in an Ames assay, an in vitro micronucleus assay, and an in vivo rat micronucleus assay when dosed orally up to 2000 mg/kg. The combined properties of this novel benzoxaborole

  为了确定具有令人满意的抗疟活性，理化性质，药代动力学特征，体内功效和安全性特征的分子，对羧酰胺基吡嗪酰氧基苯并氧杂硼酸酯进行了研究。这项优化工作发现了46个，满足了我们的目标候选人档案。化合物46对培养的恶性疟原虫具有优异的活性，并且在感染的小鼠体内对恶性疟原虫和伯氏疟原虫具有体内活性。它在小鼠，大鼠和狗中表现出良好的PK特性。它对其他11种恶性疟原虫非常活跃菌株，大多数对氯喹和乙胺嘧啶有抗性。46种体外快速寄生虫减少和体内寄生虫清除率特征与青蒿素和氯喹（两种速效抗疟药）相似。当口服剂量高达2000 mg / kg时，在Ames分析，体外微核分析和体内大鼠微核分析中均无遗传毒性。这种新颖的苯并氧杂硼酸酯的综合性能支持其向临床前发展的进程。
• [EN] OXYPYRIMIDINES AS SYK MODULATORS<br/>[FR] OXYPYRIMIDINES EN TANT QUE MODULATEURS DE SYK
  申请人：PORTOLA PHARM INC

  公开号：WO2012061415A1

  公开（公告）日：2012-05-10

  The present invention is directed to compounds of formula (I) and tautomers thereof or pharmaceutically acceptable salts, esters, and prodrugs thereof which arc inhibitor of Syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition Syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by Syk kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.

  本发明涉及式(I)的化合物及其互变异构体或药用可接受的盐、酯和前药，其为Syk激酶的抑制剂。本发明还涉及用于制备这种化合物的中间体，该化合物的制备，含有该化合物的药物组合物，抑制Syk激酶活性的方法，抑制血小板聚集的方法，以及预防或治疗至少部分由Syk激酶活性介导的多种疾病的方法，如不良血栓形成和非霍奇金淋巴瘤。
• Inhibitors of syk and JAK protein kinases
  申请人：Jia Zhaozhong

  公开号：US20100048567A1

  公开（公告）日：2010-02-25

  The present invention is directed to compounds of formula I-V and tautomers thereof or pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.

  本发明涉及公式I-V的化合物及其互变异构体或药学上可接受的盐、酯和前药，其是syk激酶的抑制剂。本发明还涉及用于制备这种化合物的中间体，制备这种化合物的方法，包含这种化合物的制药组合物，抑制syk激酶活性的方法，抑制血小板聚集的方法，以及预防或治疗至少部分由syk激酶活性介导的多种疾病的方法，例如不良血栓和非何杰金淋巴瘤。
• [EN] 2,6,9-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE N THE TREATMENT OF PROLIFERATIVE DISORDERS<br/>[FR] DERIVES DE PURINE 2,6,9-SUBSTITUES ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES PROLIFERANTES
  申请人：CYCLACEL LTD

  公开号：WO2003002565A1

  公开（公告）日：2003-01-09

  The present invention relates to compounds of formula I or a pharmaceutically acceptable salt thereof wherein R2 is 3-hydroxypiperidin-1-yl, or NHCH(R4)CH(R3) OH, wherein R3 is hydrogen or methyl and R4 is methyl, ethyl or isopropyl; R6 is 3-nitrophenylarnino, 3,4-dimethoxybenzylarnino, pyrid-2-yl-methylamino, pyrid-4-yl-methylamino or indan-5-amino; R9 is isopropyl or cyclopentanyl. In a further aspect, the invention relates to pharmaceutical compositions comprising said compounds, and the use thereof in treating antiproliferative disorders and/or viral disorders.

  本发明涉及公式I的化合物或其药学上可接受的盐，其中R2为3-羟基哌啶-1-基或NHCH（R4）CH（R3）OH，其中R3为氢或甲基，R4为甲基、乙基或异丙基；R6为3-硝基苯胺基、3,4-二甲氧基苄胺基、吡啶-2-基甲基氨基、吡啶-4-基甲基氨基或茚-5-基氨基；R9为异丙基或环戊基。在另一个方面，本发明涉及包含所述化合物的药物组合物，以及它们在治疗抗增殖性疾病和/或病毒性疾病中的应用。
• New purine derivatives
  申请人：Fischer Martin Peter

  公开号：US20050256142A1

  公开（公告）日：2005-11-17

  The present invention relates to compounds of formula 1 or pharmaceutically acceptable salts thereof, wherein one of R 1 and R 2 is methyl, ethyl or isopropyl, and the other is H; R 3 and R 4 are each independently H, branched or unbranched C 1 -C 6 alkyl, or aryl, and wherein at least one of R 3 and R 4 is other than H; R 5 is a branched or unbranched C 1 -C 5 alkyl group or a C 1 -C 6 cycloalkyl group, each of which may be optionally substituted with one or more OH groups; R 6 , R 7 , R 8 and R 9 are each independently H, halogen, NO 2 , OH, OMe, CN, NH 2 , COOH, CONH 2 , or SO 2 NH 2 . A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, CNS disorders, diabetes, stroke, alopecia or neurodegenerative disorders.

  本发明涉及公式1的化合物或其药学上可接受的盐，其中R1和R2中的一个是甲基、乙基或异丙基，另一个是氢；R3和R4各自独立地是氢、支链或非支链的C1-C6烷基，或芳基，其中至少一个是非氢基；R5是支链或非支链的C1-C5烷基或C1-C6环烷基，每个基团可以选择性地被一个或多个羟基取代；R6、R7、R8和R9各自独立地是氢、卤素、NO2、羟基、OMe、CN、NH2、COOH、CONH2或SO2NH2。本发明的另一个方面涉及包括公式1化合物的药物组合物，以及使用该化合物治疗增生性疾病、病毒性疾病、中枢神经系统疾病、糖尿病、中风、脱发或神经退行性疾病的用途。